BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.64 USD
+0.01 (0.13%)
Updated Aug 16, 2024 03:59 PM ET
After-Market: $7.64 0.00 (0.00%) 5:48 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Earnings News For BCRX
-
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
-
BioCryst: Q2 Earnings Snapshot
-
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
-
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
-
BioCryst: Q1 Earnings Snapshot
-
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
-
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
-
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
-
BioCryst: Q4 Earnings Snapshot
-
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
-
BioCryst: Q3 Earnings Snapshot
-
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
-
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
-
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
-
BioCryst: Q1 Earnings Snapshot
-
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
-
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
-
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
-
BioCryst: Q4 Earnings Snapshot
-
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
-
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
-
BioCryst: Q3 Earnings Snapshot
-
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones